John E. Brush
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
John E. Brush has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
Harlan M. Krumholz
Center for Outcomes Research and Evaluation, Yale-New Haven Hospital, New Haven, Connecticut, USA; Department of Health Policy and Management, Yale School of Public Health, New Haven, Connecticut, USA
6 shared publicationsJohn S. Burrows
Sentara Health
5 shared publicationsMark Anderson
Sentara Health
5 shared publicationsPatrick Young
Yale School of Medicine
5 shared publications- Yuan Lu
Center for Outcomes Research and Evaluation, Yale New Haven Hospital
5 shared publications Jordan R. Asher
Sentara Health Research Center, Sentara Health, Norfolk, Virginia, USA
4 shared publications
Latest Publications
- Open Access
- 6 October 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (19) , e051284
Missed Opportunities for Stroke Prevention in Patients With Hypertension: A Retrospective Case–Control Study
Background: Hypertension is the leading modifiable risk factor for ischemic stroke, yet the adequacy of preventative hypertension care in routine clinical practice remains suboptimal, potentially representing missed opportunities for stroke prevention. We evaluated the association between hypertension care delivery and incident ischemic stroke. Methods: We conducted a retrospective, matched, nested case–control study among adults with hypertension using data from a large regional health system (2010–2024). Patients with a first‐ever ischemic stroke were matched 1:2 to controls on age, sex, race and ethnicity, and calendar time. Three care metrics were assessed: (1) outpatient visits with blood pressure measurement per year; (2) number of antihypertensive medication ingredients; and (3) medication intensification score. Conditional logistic regression estimated adjusted odds ratios. Results: The study included 13 476 cases and 26 952 matched controls. Cases had fewer blood pressure visits per year (median, 2.50 versus 3.01), similar number of medication ingredients (2.00 versus 2.00), and lower treatment intensification scores (−0.211 versus −0.125). Compared with ≤1 visit, >5 blood pressure visits per year was associated with lower stroke odds (adjusted odds ratio, 0.55 [95% CI, 0.51–0.59]). Use of 2 to 3 medication ingredients (versus 0) was also associated with reduced stroke odds (adjusted odds ratio, 0.80 [95% CI, 0.75–0.86]), whereas >3 ingredients was not. The highest quartile of treatment intensification showed the strongest association (adjusted odds ratio, 0.47 [95% CI, 0.44–0.51]). Findings were consistent across subgroup and sensitivity analyses. Conclusions: Greater engagement in hypertension care was associated with lower odds of ischemic stroke, suggesting that gaps in routine management may represent missed opportunities for prevention.
- 6 October 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (19) , e051284
Open AccessMissed Opportunities for Stroke Prevention in Patients With Hypertension: A Retrospective Case–Control Study
Background: Hypertension is the leading modifiable risk factor for ischemic stroke, yet the adequacy of preventative hypertension care in routine clinical practice remains suboptimal, potentially representing missed opportunities for stroke prevention. We evaluated the association between hypertension care delivery and incident ischemic stroke. Methods: We conducted a retrospective, matched, nested case–control study among adults with hypertension using data from a large regional health system (2010–2024). Patients with a first‐ever ischemic stroke were matched 1:2 to controls on age, sex, race and ethnicity, and calendar time. Three care metrics were assessed: (1) outpatient visits with blood pressure measurement per year; (2) number of antihypertensive medication ingredients; and (3) medication intensification score. Conditional logistic regression estimated adjusted odds ratios. Results: The study included 13 476 cases and 26 952 matched controls. Cases had fewer blood pressure visits per year (median, 2.50 versus 3.01), similar number of medication ingredients (2.00 versus 2.00), and lower treatment intensification scores (−0.211 versus −0.125). Compared with ≤1 visit, >5 blood pressure visits per year was associated with lower stroke odds (adjusted odds ratio, 0.55 [95% CI, 0.51–0.59]). Use of 2 to 3 medication ingredients (versus 0) was also associated with reduced stroke odds (adjusted odds ratio, 0.80 [95% CI, 0.75–0.86]), whereas >3 ingredients was not. The highest quartile of treatment intensification showed the strongest association (adjusted odds ratio, 0.47 [95% CI, 0.44–0.51]). Findings were consistent across subgroup and sensitivity analyses. Conclusions: Greater engagement in hypertension care was associated with lower odds of ischemic stroke, suggesting that gaps in routine management may represent missed opportunities for prevention.
- Open Access
- 7 July 2025
- Published by Elsevier in JACC: Advances
- Vol. 4 (8) , 101912
Association Between Neighborhood-Level Social Vulnerability and Hypertension Outcomes
- 7 July 2025
- Published by Elsevier in JACC: Advances
- Vol. 4 (8) , 101912
Open AccessAssociation Between Neighborhood-Level Social Vulnerability and Hypertension Outcomes
- Open Access
- 1 July 2025
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 8 (7) , e2520498
Delayed Hypertension Diagnosis and Its Association With Cardiovascular Treatment and Outcomes
Importance: Hypertension is a major risk factor for cardiovascular disease, yet delays in diagnosis may limit timely treatment initiation and increase cardiovascular risk.Objectives: To examine the timing of clinical hypertension diagnosis, its association with antihypertensive medication prescribing, and its association with long-term cardiovascular outcomes.Design, Setting, and Participants: This retrospective cohort study analyzed electronic health record (EHR) data from an integrated health care system. Adults aged 18 to 85 years with at least 2 outpatient blood pressure (BP) readings of 140/90 mm Hg or more recorded at least 30 days apart from January 1, 2010, to December 31, 2021, were included (meeting BP-based criteria for hypertension as recorded in the EHR; ie, a “computed hypertension diagnosis”). Data were analyzed from January to November 2023.Exposures: The timing of clinical hypertension diagnosis (the formal recorded diagnosis by a clinician) relative to the second elevated BP measurement was categorized as (1) preexisting diagnosis; (2) diagnosed between the first and second BP elevations (reference group); (3) diagnosed after the second BP elevation, subdivided into 1 to 90 days, 91 to 365 days, or more than 365 days after the second BP elevation; and (4) no recorded diagnosis.Main Outcomes and Measures: The primary outcome was antihypertensive medication prescription within 30 days of diagnosis. The secondary outcome was the 5-year composite risk of myocardial infarction, ischemic stroke, or heart failure hospitalization. A multivariable Cox proportional hazards regression model estimated hazard ratios (HRs) for cardiovascular outcomes, adjusting for demographics, BP, and comorbidities.Results: Among 311 743 patients with a computed hypertension diagnosis, 14.6% received a diagnosis after the second BP elevation (mean [SD] age 57.9 [13.1] years; 53.3% women; 69.6% non-Hispanic White, 24.9% non-Hispanic Black, 2.4% Hispanic or Latino, and 1.7% non-Hispanic Asian). Delayed diagnosis was associated with lower antihypertensive medication prescription rates (30.6% vs 75.2%; P < .001) and increased cardiovascular risk over 5 years (delay of 1-90 days: HR, 1.04 [95% CI, 0.95-1.13]; delay of 91-365 days: HR, 1.11 [95% CI, 1.04-1.19]; and delay of >365 days: HR, 1.29 [95% CI, 1.23-1.36]). Greater delay in clinical diagnosis of hypertension was associated with younger age (45-64 years: median delay, 17.5 months [IQR, 6.1-34.6 months] vs ≥75 years: median delay, 13.4 months [IQR, 4.7-28.2 months]; P < .001), female sex (median delay, 16.6 months [IQR, 5.8-33.7 months] vs male sex: median delay, 16.1 months [IQR, 5.7-33.1 months]; P < .001), and non-Hispanic Asian or non-Hispanic Black race (non-Hispanic Asian: median delay, 18.5 months [IQR, 6.9-34.0 months]; non-Hispanic Black: median delay, 17.2 months [IQR, 5.8-34.9 months]; vs non-Hispanic White: median delay, 16.3 months [IQR, 5.9-33.3 months]).Conclusions and Relevance: This study suggests that delays in hypertension diagnosis were common and significantly associated with delays in treatment initiation and adverse cardiovascular outcomes, underscoring the need for earlier identification and intervention.
- 1 July 2025
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 8 (7) , e2520498
Open AccessDelayed Hypertension Diagnosis and Its Association With Cardiovascular Treatment and Outcomes
Importance: Hypertension is a major risk factor for cardiovascular disease, yet delays in diagnosis may limit timely treatment initiation and increase cardiovascular risk.Objectives: To examine the timing of clinical hypertension diagnosis, its association with antihypertensive medication prescribing, and its association with long-term cardiovascular outcomes.Design, Setting, and Participants: This retrospective cohort study analyzed electronic health record (EHR) data from an integrated health care system. Adults aged 18 to 85 years with at least 2 outpatient blood pressure (BP) readings of 140/90 mm Hg or more recorded at least 30 days apart from January 1, 2010, to December 31, 2021, were included (meeting BP-based criteria for hypertension as recorded in the EHR; ie, a “computed hypertension diagnosis”). Data were analyzed from January to November 2023.Exposures: The timing of clinical hypertension diagnosis (the formal recorded diagnosis by a clinician) relative to the second elevated BP measurement was categorized as (1) preexisting diagnosis; (2) diagnosed between the first and second BP elevations (reference group); (3) diagnosed after the second BP elevation, subdivided into 1 to 90 days, 91 to 365 days, or more than 365 days after the second BP elevation; and (4) no recorded diagnosis.Main Outcomes and Measures: The primary outcome was antihypertensive medication prescription within 30 days of diagnosis. The secondary outcome was the 5-year composite risk of myocardial infarction, ischemic stroke, or heart failure hospitalization. A multivariable Cox proportional hazards regression model estimated hazard ratios (HRs) for cardiovascular outcomes, adjusting for demographics, BP, and comorbidities.Results: Among 311 743 patients with a computed hypertension diagnosis, 14.6% received a diagnosis after the second BP elevation (mean [SD] age 57.9 [13.1] years; 53.3% women; 69.6% non-Hispanic White, 24.9% non-Hispanic Black, 2.4% Hispanic or Latino, and 1.7% non-Hispanic Asian). Delayed diagnosis was associated with lower antihypertensive medication prescription rates (30.6% vs 75.2%; P < .001) and increased cardiovascular risk over 5 years (delay of 1-90 days: HR, 1.04 [95% CI, 0.95-1.13]; delay of 91-365 days: HR, 1.11 [95% CI, 1.04-1.19]; and delay of >365 days: HR, 1.29 [95% CI, 1.23-1.36]). Greater delay in clinical diagnosis of hypertension was associated with younger age (45-64 years: median delay, 17.5 months [IQR, 6.1-34.6 months] vs ≥75 years: median delay, 13.4 months [IQR, 4.7-28.2 months]; P < .001), female sex (median delay, 16.6 months [IQR, 5.8-33.7 months] vs male sex: median delay, 16.1 months [IQR, 5.7-33.1 months]; P < .001), and non-Hispanic Asian or non-Hispanic Black race (non-Hispanic Asian: median delay, 18.5 months [IQR, 6.9-34.0 months]; non-Hispanic Black: median delay, 17.2 months [IQR, 5.8-34.9 months]; vs non-Hispanic White: median delay, 16.3 months [IQR, 5.9-33.3 months]).Conclusions and Relevance: This study suggests that delays in hypertension diagnosis were common and significantly associated with delays in treatment initiation and adverse cardiovascular outcomes, underscoring the need for earlier identification and intervention.
- Open Access
- 7 April 2025
- Published by Elsevier in American Heart Journal Plus: Cardiology Research and Practice
- Vol. 53, 100540
Real-world interventional outcomes for cardiogenic shock complicating acute myocardial infarction
- 7 April 2025
- Published by Elsevier in American Heart Journal Plus: Cardiology Research and Practice
- Vol. 53, 100540
Open AccessReal-world interventional outcomes for cardiogenic shock complicating acute myocardial infarction
- Open Access
- 8 August 2024
- Published by Elsevier in JACC: Advances
- Vol. 3 (9) , 101177
Effect of the COVID-19 Pandemic on Monitoring and Control of Cardiovascular Risk Factors and Disparities
- 8 August 2024
- Published by Elsevier in JACC: Advances
- Vol. 3 (9) , 101177
Open AccessEffect of the COVID-19 Pandemic on Monitoring and Control of Cardiovascular Risk Factors and Disparities
- Open Access
- 7 May 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (9) , e033253
Hypertension Trends and Disparities Over 12 Years in a Large Health System: Leveraging the Electronic Health Records
Background: The digital transformation of medical data enables health systems to leverage real‐world data from electronic health records to gain actionable insights for improving hypertension care. Methods and Results: We performed a serial cross‐sectional analysis of outpatients of a large regional health system from 2010 to 2021. Hypertension was defined by systolic blood pressure ≥140 mm Hg, diastolic blood pressure ≥90 mm Hg, or recorded treatment with antihypertension medications. We evaluated 4 methods of using blood pressure measurements in the electronic health record to define hypertension. The primary outcomes were age‐adjusted prevalence rates and age‐adjusted control rates. Hypertension prevalence varied depending on the definition used, ranging from 36.5% to 50.9% initially and increasing over time by ≈5%, regardless of the definition used. Control rates ranged from 61.2% to 71.3% initially, increased during 2018 to 2019, and decreased during 2020 to 2021. The proportion of patients with a hypertension diagnosis ranged from 45.5% to 60.2% initially and improved during the study period. Non‐Hispanic Black patients represented 25% of our regional population and consistently had higher prevalence rates, higher mean systolic and diastolic blood pressure, and lower control rates compared with other racial and ethnic groups. Conclusions: In a large regional health system, we leveraged the electronic health record to provide real‐world insights. The findings largely reflected national trends but showed distinctive regional demographics and findings, with prevalence increasing, one‐quarter of the patients not controlled, and marked disparities. This approach could be emulated by regional health systems seeking to improve hypertension care.
- 7 May 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (9) , e033253
Open AccessHypertension Trends and Disparities Over 12 Years in a Large Health System: Leveraging the Electronic Health Records
Background: The digital transformation of medical data enables health systems to leverage real‐world data from electronic health records to gain actionable insights for improving hypertension care. Methods and Results: We performed a serial cross‐sectional analysis of outpatients of a large regional health system from 2010 to 2021. Hypertension was defined by systolic blood pressure ≥140 mm Hg, diastolic blood pressure ≥90 mm Hg, or recorded treatment with antihypertension medications. We evaluated 4 methods of using blood pressure measurements in the electronic health record to define hypertension. The primary outcomes were age‐adjusted prevalence rates and age‐adjusted control rates. Hypertension prevalence varied depending on the definition used, ranging from 36.5% to 50.9% initially and increasing over time by ≈5%, regardless of the definition used. Control rates ranged from 61.2% to 71.3% initially, increased during 2018 to 2019, and decreased during 2020 to 2021. The proportion of patients with a hypertension diagnosis ranged from 45.5% to 60.2% initially and improved during the study period. Non‐Hispanic Black patients represented 25% of our regional population and consistently had higher prevalence rates, higher mean systolic and diastolic blood pressure, and lower control rates compared with other racial and ethnic groups. Conclusions: In a large regional health system, we leveraged the electronic health record to provide real‐world insights. The findings largely reflected national trends but showed distinctive regional demographics and findings, with prevalence increasing, one‐quarter of the patients not controlled, and marked disparities. This approach could be emulated by regional health systems seeking to improve hypertension care.
- Open Access
Hypertension Trends and Disparities over Twelve Years in a Large Health System: Leveraging the Electronic Health Records
Background: The digital transformation of medical data enables health systems to leverage real-world data (RWD) from electronic health records (EHR) to gain actionable insights for improving hypertension care. Methods: We performed a serial cross-sectional analysis of outpatients of a large regional health system from 2010 to 2021. Hypertension was defined by systolic blood pressure (SBP) ≥ 140 mmHg or diastolic blood pressure (DBP) ≥ 90 mmHg) or recorded treatment with anti-hypertension medications. We evaluated four methods of using blood pressure measurements in the EHR to define hypertension. The primary outcomes were age-adjusted prevalence rates and age-adjusted control rates. Secondary outcomes were age-adjusted mean SBP and DBP and age-adjusted proportion of patients with a searchable diagnosis code of hypertension in the EHR. Results: Hypertension prevalence varied depending on the definition used, ranging from 36.5% to 50.9% initially and increasing over time by approximately 5%, regardless of the definition used. Control rates ranged from 61.2% to 71.3% initially, rose during 2018-2019 and fell during 2020-2021. The proportion of patients with a hypertension diagnosis ranged from 45.5% to 60.2% initially and improved during the study period. Non-Hispanic Black patients represented 25% of our regional population and consistently had higher prevalence rates, higher mean SBP and DBP and lower control rates compared with other racial and ethnic groups. Conclusion: In a large regional health system, we leveraged the EHR to provide real-world insights. The findings largely reflected national trends but showed distinctive regional demographics and findings. The findings have provided opportunities for improvement, with prevalence increasing, a quarter of the patients not controlled, and marked disparities. This approach could be emulated by regional health systems seeking to improve hypertension care. Key Points: Question: Can a large regional health system leverage the electronic health record to analyze hypertension trends and disparities to drive improvement? Findings: We analyzed 1,376,325 patients over 12 years and found that age-adjusted hypertension prevalence increased by approximately 5%. Age-adjusted hypertension control rates were in the 70% range and remained stable. Non-Hispanic Black patients represented 25% of our specific regional population and had 12-14% higher hypertension prevalence rates, higher mean age-adjusted systolic and diastolic blood pressure, and lower hypertension control rates compared with other racial groups. Meaning: Real world data can provide actionable insights about hypertension and disparities in a specific region that could inform regional system strategies and initiatives for improvement.
Open AccessHypertension Trends and Disparities over Twelve Years in a Large Health System: Leveraging the Electronic Health Records
Background: The digital transformation of medical data enables health systems to leverage real-world data (RWD) from electronic health records (EHR) to gain actionable insights for improving hypertension care. Methods: We performed a serial cross-sectional analysis of outpatients of a large regional health system from 2010 to 2021. Hypertension was defined by systolic blood pressure (SBP) ≥ 140 mmHg or diastolic blood pressure (DBP) ≥ 90 mmHg) or recorded treatment with anti-hypertension medications. We evaluated four methods of using blood pressure measurements in the EHR to define hypertension. The primary outcomes were age-adjusted prevalence rates and age-adjusted control rates. Secondary outcomes were age-adjusted mean SBP and DBP and age-adjusted proportion of patients with a searchable diagnosis code of hypertension in the EHR. Results: Hypertension prevalence varied depending on the definition used, ranging from 36.5% to 50.9% initially and increasing over time by approximately 5%, regardless of the definition used. Control rates ranged from 61.2% to 71.3% initially, rose during 2018-2019 and fell during 2020-2021. The proportion of patients with a hypertension diagnosis ranged from 45.5% to 60.2% initially and improved during the study period. Non-Hispanic Black patients represented 25% of our regional population and consistently had higher prevalence rates, higher mean SBP and DBP and lower control rates compared with other racial and ethnic groups. Conclusion: In a large regional health system, we leveraged the EHR to provide real-world insights. The findings largely reflected national trends but showed distinctive regional demographics and findings. The findings have provided opportunities for improvement, with prevalence increasing, a quarter of the patients not controlled, and marked disparities. This approach could be emulated by regional health systems seeking to improve hypertension care. Key Points: Question: Can a large regional health system leverage the electronic health record to analyze hypertension trends and disparities to drive improvement? Findings: We analyzed 1,376,325 patients over 12 years and found that age-adjusted hypertension prevalence increased by approximately 5%. Age-adjusted hypertension control rates were in the 70% range and remained stable. Non-Hispanic Black patients represented 25% of our specific regional population and had 12-14% higher hypertension prevalence rates, higher mean age-adjusted systolic and diastolic blood pressure, and lower hypertension control rates compared with other racial groups. Meaning: Real world data can provide actionable insights about hypertension and disparities in a specific region that could inform regional system strategies and initiatives for improvement.
- 14 April 2023
- Published by Elsevier in The American Journal of Cardiology
- Vol. 197, 101-107
Sex Differences in Symptom Complexity and Door-to-Balloon Time in Patients With ST-Elevation Myocardial Infarction
- 14 April 2023
- Published by Elsevier in The American Journal of Cardiology
- Vol. 197, 101-107
Sex Differences in Symptom Complexity and Door-to-Balloon Time in Patients With ST-Elevation Myocardial Infarction